At the heart of the investigation lies a comprehensive multi-omics approach integrating transcriptomic and glycoproteomic analyses of epididymal white adipose tissue (eWAT) harvested from both young and aged murine models. Through RNA sequencing, the researchers detected a marked downregulation of key adipogenic genes in aged tissue, an observation consistent with diminished capacity for fat cell differentiation and metabolic function. Concurrently, genes linked to inflammation and fibrosis were significantly upregulated, outlining a clear molecular signature of adipose tissue deterioration driven by aging processes.

Going beyond transcriptomics, the study employed state-of-the-art N- and O-glycoproteomic profiling which illuminated widespread alterations in protein glycosylation patterns in the aged eWAT microenvironment. Notably, glycoproteins showing differential glycosylation were predominantly localized to the extracellular matrix and extracellular space, implicating these modifications in modulating cell–matrix interactions, immune signaling pathways, and the innate immune response. These findings underscore the complexity of aging-related systemic changes, highlighting glycosylation as a dynamic modulator of tissue physiology.

Among the glycosylation changes, N-fucosylation of IgG subclasses (IgG1, IgG2a, and IgG3) was significantly elevated in aged adipose tissue, while only IgG2a exhibited increased O-fucosylation. This selective enhancement of fucosylation points to a subtype-specific regulation of IgG glycans during aging, with functional implications. The aberrant fucosylation of IgG molecules not only serves as a molecular hallmark of aging but may actively contribute to the dysregulated inflammatory milieu observed in senescent adipose tissue.

To causally interrogate the role of fucosylated IgG in vivo, the researchers developed a sophisticated animal model involving B-cell depletion in aged mice to reduce endogenous IgG levels. This manipulation led to a restoration of adipogenic gene expression and a suppression of fibrotic markers, indicating that IgG plays a direct role in mediating tissue remodeling and metabolic balance. Crucially, reconstitution experiments with either fucosylated or nonfucosylated IgG revealed stark differences; fucosylated IgG exacerbated inflammation and fibrosis while more profoundly inhibiting the adipogenic program compared to its nonfucosylated counterpart.

The evidence collectively points to fucosylated IgG as a pathogenic driver of age-associated adipose tissue dysfunction, operating through mechanisms that enhance chronic inflammation and tissue fibrosis while impairing fat cell regeneration. These effects likely contribute to systemic metabolic decline, insulin resistance, and the progression of age-related diseases such as type 2 diabetes and cardiovascular disorders. The molecular details highlighted in this study open new avenues for interventions that could selectively target IgG glycosylation profiles to mitigate metabolic aging.

Intriguingly, this research places the immune system’s adaptive arm—and specifically the post-translational modification of antibodies—at the nexus of metabolic regulation in aging. It expands the paradigm beyond classical immunosenescence by demonstrating how glycan remodeling on IgG alters tissue homeostasis and inflammatory set points. This conceptual advance underscores the importance of glycoimmunology in understanding complex age-related pathologies and devising novel therapeutic strategies.

From a translational perspective, modulating IgG fucosylation could become a promising strategy to rejuvenate aging adipose tissue function and thus improve metabolic healthspan. Potential approaches may include the development of small molecule inhibitors targeting fucosyltransferases, glycoengineering of therapeutic antibodies, or immune-modulating therapies that recalibrate IgG glycosylation patterns. Furthermore, circulating fucosylated IgG levels might serve as valuable biomarkers to monitor adipose dysfunction and metabolic risk in aging populations.

The study also highlights the broader importance of extracellular matrix remodeling and glycoprotein signaling networks in adipose tissue aging. Alterations in glycosylation of extracellular proteins appear to coordinate inflammatory cell infiltration, fibrotic remodeling, and impaired adipogenesis. These multifaceted modifications suggest a highly orchestrated process whereby glycan changes propagate age-related tissue dysfunction, thus establishing glycosylation as both a marker and mediator of systemic aging processes.

Overall, the identification of fucosylated IgG as a critical molecular mediator connecting the immune system with metabolic decline represents a significant step forward in aging research. It challenges existing dogmas and invites a rethinking of how immune glycoproteins influence organ function over the lifespan. This innovative work paves the way for new scientific inquiries into the roles of antibody glycosylation in other age-related tissues and diseases, potentially revolutionizing the field of immunometabolism.

The full research article titled “Fucosylated IgG Contributes to Adipose Tissue Dysfunction During Aging” was authored by Jingyu Wang, Wei Su, Haotian Wang, Licui Liu, Jinlong Li, and Youxin Wang. Published on February 17, 2026, in Engineering, the paper is accessible via open access and provides comprehensive experimental details and data supporting these novel findings. Interested readers and researchers can explore the full text at: https://doi.org/10.1016/j.eng.2025.10.008.

Subject of Research: The role of fucosylated immunoglobulin G in adipose tissue dysfunction and aging-related metabolic decline.

Article Title: Fucosylated IgG Contributes to Adipose Tissue Dysfunction During Aging

News Publication Date: 17-Feb-2026

Web References:
https://doi.org/10.1016/j.eng.2025.10.008
https://www.sciencedirect.com/journal/engineering

Image Credits: Jingyu Wang, Wei Su et al.

Keywords

Aging, fucosylated IgG, adipose tissue dysfunction, glycosylation, immunoglobulin G, metabolic disorders, inflammation, fibrosis, transcriptomics, glycoproteomics, immunometabolism, B-cell depletion, extracellular matrix.

The heart’s ability to recover after a myocardial infarction is heavily dependent on the formation of new blood vessels—a process known as angiogenesis. This reparative vascular growth is notoriously impaired in diabetic conditions, dramatically worsening patient outcomes. Historically, the molecular mechanisms underpinning this angiogenic deficit have remained elusive, but this study emphasizes an unexpected regulatory axis involving the post-translational lactylation of isocitrate dehydrogenase 2 (IDH2), a mitochondrial enzyme traditionally known for its role in the tricarboxylic acid (TCA) cycle.

IDH2 usually functions within the mitochondria to catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, generating NADPH and maintaining redox balance. However, this study reveals that under diabetic myocardial infarction conditions, IDH2 undergoes lactylation—a newly recognized post-translational modification induced by elevated lactate levels, which accumulate as a consequence of altered glucose metabolism in diabetes. This modification alters IDH2’s interaction landscape, extending its influence beyond metabolic control to modulate vascular endothelial signaling.

The mechanism by which lactylated IDH2 impairs angiogenesis involves its interference with the interaction between caveolin-1 (Cav1) and endothelial nitric oxide synthase (eNOS). Typically, Cav1 acts as a scaffolding protein within caveolae—specialized invaginations of the endothelial plasma membrane—regulating eNOS enzymatic activity, which is critical for the production of nitric oxide (NO). NO is a potent vasodilator and a critical signaling molecule promoting angiogenesis. The study documents that lactylation of IDH2 perturbs Cav1-eNOS binding, effectively diminishing eNOS activation and NO output.

This blockade of the Cav1-eNOS interaction represents a significant metabolic checkpoint linking aberrant metabolic states to endothelial dysfunction. It underscores a sophisticated mechanism by which diabetic myocardial infarction exacerbates vascular insufficiency, as endothelial cells deprived of NO signaling fail to proliferate or migrate adequately. Intriguingly, this finding aligns with the emerging concept that post-translational modifications beyond phosphorylation, such as lactylation, serve as critical signaling modulators in pathophysiological contexts.

The researchers employed a murine model of diabetic myocardial infarction, administering inducible genetic and pharmacological tools to manipulate IDH2 lactylation. Through comprehensive biochemical analyses, including immunoprecipitation and mass spectrometry, they mapped lactylation sites on IDH2 and demonstrated the direct consequences of these modifications on protein-protein interactions within the endothelium. Functional assays confirmed impaired angiogenic capacity in lactylated IDH2-expressing endothelial cells, alongside diminished NO production—compelling evidence linking these molecular events to physiological outcomes.

Importantly, reversing IDH2 lactylation restored Cav1-eNOS interaction and endothelial function, highlighting therapeutic potential. Using lactylation inhibitors or mimetics that disrupt this post-translational mark, the team was able to rescue angiogenesis in diabetic infarcted hearts. This not only confirms the causality of IDH2 lactylation in the observed phenotype but also suggests promising biomedical interventions aimed at promoting cardiac repair in diabetes, a population notoriously susceptible to poor recovery following ischemic injury.

Beyond the immediate implications for myocardial infarction, these findings shed light on a broader metabolic-vasculature interface where lactate metabolism, once considered merely a waste product, emerges as a critical signaling molecule capable of modulating protein function and intercellular communication. This paradigm shift compels the field to reconsider metabolic byproducts as active participants in disease processes, particularly through mechanisms like protein lactylation.

Furthermore, this study enriches the understanding of caveolae biology. Cav1 has been shown to modulate various signaling molecules, but its role as a mediator of eNOS activity under metabolic stress conditions highlights caveolae as dynamic platforms sensitive to intracellular metabolic states. The disruption of these microdomains, induced by altered IDH2 post-translational modifications, exemplifies how metabolic dysregulation can translate into architectural and signaling alterations within endothelial cells.

The rigorous approach of combining metabolic profiling, protein chemistry, molecular biology, and in vivo physiological assessment adds robust credibility to these conclusions. This integrative methodology provides a comprehensive view of how metabolic stress and lactate accumulation directly impact angiogenic signaling pathways during critical phases of cardiac repair under diabetic stress.

Clinically, these insights offer hope for the development of targeted therapies aimed at mitigating diabetic vascular complications by modulating lactylation pathways or stabilizing Cav1-eNOS interactions. Given the high global burden of diabetes mellitus and its associated cardiovascular sequelae, such translational advances could significantly reduce morbidity and mortality.

Moreover, the unveiling of IDH2 lactylation as a regulatory node raises questions about the potential roles of similar modifications in other tissues and diseases characterized by metabolic dysregulation and vascular impairment. Future studies could explore lactylation as a widespread modulatory mechanism, possibly implicated in tumor angiogenesis, chronic inflammation, or neurovascular disorders, further expanding the impact of these findings.

In conclusion, this landmark study by Zang et al. demonstrates not only a novel biochemical modification of IDH2 but intricately connects metabolic derangements characteristic of diabetes to the molecular underpinnings of impaired angiogenesis after myocardial infarction. By defining lactylation as a critical mediator of Cav1-eNOS disruption, it provides a blueprint for understanding and eventually targeting the metabolic vulnerabilities that undermine cardiovascular repair mechanisms in diabetic patients.

This research exemplifies the power of interdisciplinary investigation, merging metabolic biochemistry, vascular biology, and clinical pathology to unravel complex disease processes. It challenges conventional wisdom that separates metabolism from signaling and highlights the dynamic interplay of cellular environments in health and disease. As the field embraces this integrative perspective, findings such as these will pave the way for innovative therapeutic strategies and deeper mechanistic insights.

Continued exploration into the enzymatic regulators of protein lactylation, the identification of potential “erasers” capable of reversing this modification, and the development of specific inhibitors or enhancers will further refine our ability to manipulate this pathway. Opportunities also lie in applying high-throughput screening to identify compounds that modulate IDH2 lactylation or restore Cav1-eNOS interaction, tailoring therapies to individual metabolic and vascular profiles.

Ultimately, this discovery paints a hopeful picture for diabetic cardiovascular medicine, transforming basic metabolic insights into tangible clinical possibilities. As the nexus between metabolism and vascular biology becomes more apparent, therapeutic efforts might shift towards dynamically tuning post-translational modifications like lactylation to promote tissue repair and prevent disease progression, opening new chapters in precision medicine.

Subject of Research: The role of IDH2 lactylation in regulating angiogenesis during diabetic myocardial infarction by modulating the interaction between Cav1 and eNOS in endothelial cells.

Article Title: IDH2 lactylation promotes angiogenesis in murine diabetic myocardial infarction via blocking Cav1-eNOS interaction.

Article References:
Zang, G., Xu, S., Sun, Z. et al. IDH2 lactylation promotes angiogenesis in murine diabetic myocardial infarction via blocking Cav1-eNOS interaction. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67877-0

Image Credits: AI Generated